Topamax: Weight loss shows no immediate benefit
A study of patients taking a drug for a rare genetic disorder showed it had no effect on weight loss or its effect on metabolism.
Key points:The drug Topiramate was used to treat patients with Type 2 diabetes for 10 yearsResearchers also compared the effects of Topiramic and another drug used to reduce the risk of cardiovascular disease (CVD) to the drugs used in a similar study, but found the drugs did not differIn the study, the researchers found that patients taking Topiramine were significantly less likely to lose weight and were more likely to regain it over a 10-year period compared to patients taking other drugs for CVD.
In the current study, researchers followed 1,062 patients with type 2 diabetes from 2003 to 2014.
The study team did not know if patients taking the drug Topilamate or another drug for weight loss had a different response to Topiramycin.
But, based on the study results, the team concluded that “the potential benefits of Topilamic or Topiramcin may outweigh its risks”.
“We found that for patients with a single mutation, the combination of Topimax and Topiramin reduced the risk for C.D.I. and decreased the risk from CVD,” Dr. Roberta K. O’Malley, the lead author of the study from the Mayo Clinic in Rochester, Minnesota, told Reuters Health in an email.
“However, this benefit was only apparent in patients who took the combination for at least 10 years.
We observed no significant reduction in CVD risk.”
For patients who did not have a single mutated mutation, they had an increased risk for metabolic syndrome, which is a combination of heart disease and type 2 Diabetes.
The findings are important because it suggests that patients who are not using a specific drug or diet may be more susceptible to complications related to the disease, said Dr. Matthew S. Johnson, a cardiologist and the study’s lead author.
“These results suggest that Topimac may offer some benefit in patients with CVD but should be used cautiously, particularly for those with the most severe metabolic complications,” he said.
“If you are not taking the medications for metabolic disorders and you do not have one mutation, there is the potential that the combination may not be effective for you.”
Dr. O’thalia said it was possible that the findings could be due to the drug’s longer half-life, or that patients were less sensitive to its effects when taking it for a longer time.
“Although these results are encouraging, we are still unsure if the long half-lives of Topalamycin and Topilamycin may have contributed to these results,” she said.
Topiramate is a long-acting insulin-like growth factor-1 inhibitor that inhibits the growth of insulin-producing beta cells in the pancreas.
It has also been shown to help with weight loss and metabolic disorders in people with type 1 diabetes.
A study published last month in the Journal of Clinical Endocrinology and Metabolism found that the drug could reduce the number of people with Type 1 diabetes by up to 40%.
The researchers also found that people taking the combination had an increase in the risk to develop Type 2 Diabetes, a more severe form of the disease.
The Mayo Clinic has not yet announced whether it will test the drug in people who have metabolic complications from it.
Dr. Johnson said the study also revealed that patients using the drug had a lower risk of experiencing heart attacks and stroke.
“For patients with the same mutation, we did not find a significant difference in risk for those taking the combined therapy versus those taking either the Topilamaycin or Topimacliz treatment alone,” he added.
“This finding suggests that the combined treatment may offer significant benefits to patients with metabolic disorders, especially for those who have a low risk for heart attack or stroke.”SOURCE: bit.ly/2fK4pq3 BBC Science news release